Stockscreener 앱 받기
1.80
28.57%
0.40
시장 영업 전:
1.79
-0.01
-0.56%
전일 마감가:
$1.40
열려 있는:
$1.46
하루 거래량:
34.90M
Relative Volume:
8.69
시가총액:
$166.91M
수익:
-
순이익/손실:
$-69.31M
주가수익비율:
-1.4173
EPS:
-1.27
순현금흐름:
$-62.80M
1주 성능:
-82.73%
1개월 성능:
-82.00%
6개월 성능:
-59.09%
1년 성능:
-61.21%
1일 변동 폭
$1.45
$1.85
1주일 범위
$1.07
$11.16
52주 변동 폭
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
명칭
Rezolute Inc
전화
650-206-4507
주소
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
RZLT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
1.80 | 129.82M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-11 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2025-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-08-27 | 개시 | Guggenheim | Buy |
| 2024-07-17 | 개시 | BTIG Research | Buy |
| 2024-06-04 | 개시 | Craig Hallum | Buy |
| 2024-04-09 | 개시 | Maxim Group | Buy |
| 2022-08-02 | 재개 | Canaccord Genuity | Buy |
| 2022-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-09-08 | 개시 | ROTH Capital | Buy |
| 2021-05-27 | 개시 | Oppenheimer | Outperform |
| 2021-05-25 | 개시 | H.C. Wainwright | Buy |
모두보기
Rezolute Inc 주식(RZLT)의 최신 뉴스
HC Wainwright Decreases Earnings Estimates for Rezolute - MarketBeat
Rezolute (RZLT) Is Down 82.7% After Phase 3 sunRIZE Failure in Congenital Hyperinsulinism Trial - Yahoo Finance UK
Rezolute (NASDAQ:RZLT) Downgraded by Citizens Jmp to Hold - MarketBeat
Investors Buy Large Volume of Rezolute Call Options (NASDAQ:RZLT) - MarketBeat
Guggenheim Issues Pessimistic Forecast for Rezolute (NASDAQ:RZLT) Stock Price - MarketBeat
Jefferies Raises Rezolute Price Target Amid Favorable Data Prospects - timothysykes.com
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial FailureHagens Berman Investigating - The Malaysian Reserve
Rezolute (NASDAQ:RZLT) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Rezolute stock crashes after sole pipeline candidate fails Phase III - MSN
Rezolute (NASDAQ:RZLT) Reaches New 12-Month Low on Analyst Downgrade - MarketBeat
Guggenheim Maintains Rezolute (RZLT) Buy Recommendation - Nasdaq
Jefferies Raises Rezolute’s Price Target Amid Promising Drug Prospects - StocksToTrade
RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - TradingView — Track All Markets
Rezolute stock price target slashed by H.C. Wainwright after failed study - Investing.com Canada
Jefferies Lifts Rezolute’s Target amid New Data Anticipation - timothysykes.com
Craig-Hallum downgrades Rezolute stock to Hold on failed Phase III trial - Investing.com Australia
Rezolute price target lowered to $4 from $20 at Maxim - TipRanks
Rezolute decimated on Phase III miss for ersodetug - The Pharma Letter
Rezolute stock price target slashed by Guggenheim after trial failure - Investing.com Nigeria
RZLT Maintains Buy Rating despite Guggenheim's Lowered Price Tar - GuruFocus
Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts - ts2.tech
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - PR Newswire
Craig-Hallum Downgrades Rezolute to Hold From Buy, Adjusts PT to $2 From $18 - marketscreener.com
Buy Rating Maintained for XOMA Despite Rezolute Bio’s Trial Setback, Future Developments Anticipated - TipRanks
Rezolute (RZLT): HC Wainwright & Co. Significantly Lowers Price Target | RZLT Stock News - GuruFocus
HC Wainwright & Co. Maintains Rezolute (RZLT) Buy Recommendation - Nasdaq
Rezolute price target lowered to $5 from $14 at H.C. Wainwright - TipRanks
What analysts say about Rezolute Inc 6HV1 stockProtective Put Strategies & Rapid Portfolio Growth - earlytimes.in
Praxis tees up another approval filing; Geron turns to layoffs - Yahoo Finance
Rezolute, Inc. (NASDAQ:RZLT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Rezolute fails phase 3 for RZ358 as placebo response masks 10 mg/kg efficacyCHOSUNBIZ - Chosunbiz
Failed Trials And Missed Targets Send Shares Reeling - Finimize
Rezolute stock hits 52-week low at 1.21 USD despite strong annual gain - Investing.com Canada
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure - The AI Journal
Rezolute Inc. (RZLT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Rezolute stock price target cut to $5 from $17 at BTIG after trial failure - Investing.com Nigeria
Two Biotechs Crash, One Down 88%, On Failed Insulin Drug - Investor's Business Daily
Rezolute, Inc. (RZLT): The "sunRIZE" Post-Mortem & The Tumor Hyperinsulinism Pivot (NASDAQ:RZLT) - Seeking Alpha
Why two Bay Area companies' stocks tumbled on a drug's clinical failureSan Francisco Business Times - The Business Journals
US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns - ts2.tech
Rezolute downgraded to Hold from Buy at Craig-Hallum - TipRanks
Rezolute (RZLT): Assessing Valuation After a Year of Strong Share Price Gains - Yahoo Finance
Is RZLT Stock A Hidden Gem? - StocksToTrade
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - The AI Journal
Rezolute, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – RZLT - marketscreener.com
Rezolute (RZLT) Stock: Dips Sharply After Phase 3 SunRIZE Trial Disappoints Investors - parameter.io
RZLT: Phase 3 Sunrise study for ersodetug in congenital HI failed to show significant benefit over placebo - TradingView — Track All Markets
Rezolute plunges 90% as Phase 3 sunRIZE trial for low BP fails | Tap to know more | Inshorts - Inshorts
Why Is XOMA Royalty Stock Sinking Thursday? - Benzinga
Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage - ts2.tech
Rezolute Inc (RZLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rezolute Inc 주식 (RZLT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Evans Daron | CFO |
Jun 24 '25 |
Buy |
4.05 |
5,000 |
20,250 |
268,900 |
| Kim Young-Jin | Director |
Jun 13 '25 |
Buy |
3.25 |
1,230,769 |
3,999,999 |
8,423,386 |
| KREHER NERISSA | Director |
Jun 13 '25 |
Buy |
3.25 |
3,076 |
9,997 |
37,576 |
| Hogenhuis Wladimir | Director |
Mar 31 '25 |
Buy |
2.92 |
6,758 |
19,733 |
84,025 |
| Elam Nevan C | CEO |
Mar 27 '25 |
Buy |
2.85 |
12,302 |
34,999 |
224,119 |
| Evans Daron | CFO |
Mar 26 '25 |
Buy |
2.89 |
10,000 |
28,900 |
237,900 |
| Evans Daron | CFO |
Mar 26 '25 |
Buy |
2.88 |
10,000 |
28,800 |
23,000 |
| Hogenhuis Wladimir | Director |
Feb 18 '25 |
Buy |
4.70 |
10,000 |
47,000 |
77,267 |
| Evans Daron | CFO |
Dec 18 '24 |
Buy |
4.29 |
10,000 |
42,900 |
150,900 |
| Evans Daron | CFO |
Dec 09 '25 |
Buy |
5.04 |
10,549 |
53,167 |
131,900 |
1.08%
0.91%
자본화:
|
볼륨(24시간):